APLM Stock Summary and Trading Ideas (Apollomics - Class A | NASDAQ:APLM)

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Apollomics - Class A trades on the NASDAQ stock market under the symbol APLM.

As of May 23, 2025, APLM stock price declined to $7.08 with 11,189 million shares trading.

APLM has a market cap of $7.81 million. This is considered a Sub-Micro Cap stock.

APLM has underperformed the market in the last year with a return of -75.2%, while SPY returned +10.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in APLM shares. However, APLM has outperformed the market in the last 3 month and 2 week periods, returning +0.9% and +24.6%, while SPY returned -3.2% and +2.5%, respectively. This indicates APLM has been having a stronger performance recently.

APLM support price is $6.39 and resistance is $8.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APLM shares will trade within this expected range on the day.